Wed, Sep 17, 2014, 1:37 AM EDT - U.S. Markets open in 7 hrs 53 mins

Recent

% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • laruelucky laruelucky Mar 9, 2013 8:29 AM Flag

    quite a few GENERIC drugs out there already to treat breast cancer

    capecitabine systemic (Pro, More...)
    class: antimetabolites 1 review

    Rate it
    10
    doxorubicin systemic (Pro, More...)
    class: antibiotics/antineoplastics 0 reviews

    Rate it
    10
    paclitaxel protein-bound systemic (More...)
    class: mitotic inhibitors 2 reviews

    Rate it
    9.5
    trastuzumab systemic (Pro, More...)
    class: HER2 inhibitors 1 review

    Rate it
    9.5
    everolimus systemic (Pro, More...)
    class: mTOR inhibitors, selective immunosuppressants 1 review

    Rate it
    8.0
    paclitaxel systemic (Pro, More...)
    class: mitotic inhibitors 1 review

    Rate it
    7.0
    letrozole systemic (Pro, More...)
    class: aromatase inhibitors, hormones/antineoplastics 16 reviews

    Rate it
    6.9
    tamoxifen systemic (Pro, More...)
    class: hormones/antineoplastics, selective estrogen receptor modulators 8 reviews

    Rate it
    6.7
    exemestane systemic (Pro, More...)
    class: aromatase inhibitors, hormones/antineoplastics 11 reviews

    Rate it
    6.4
    anastrozole systemic (Pro, More...)
    class: aromatase inhibitors, hormones/antineoplastics 25 reviews

    Rate it
    6.1
    lapatinib systemic (Pro, More...)
    class: EGFR inhibitors, HER2 inhibitors 0 reviews

    Rate it
    5.0
    bevacizumab systemic (Pro, More...)
    class: VEGF/VEGFR inhibitors 0 reviews

    Rate it
    4.0
    gemcitabine systemic (Pro, More...)
    class: antimetabolites 0 reviews

    Rate it
    4.0
    docetaxel systemic (Pro, More...)
    class: mitotic inhibitors 1 review

    Rate it
    3.0
    thiotepa systemic (Pro, More...)
    class: alkylating agents 0 reviews Not rated
    Be the first
    vinblastine systemic (Pro, More...)
    class: mitotic inhibitors 0 reviews Not rated
    Be the first
    toremifene systemic (Pro, More...)
    class: hormones/antineoplastics, selective estrogen receptor modulators 0 reviews Not rated
    Be the first
    nandrolone systemic (Pro, More...)
    class: androgens and anabolic steroids 0 reviews Not rated
    Be the first
    pertuzumab systemic (Pro, More...)
    class: HER2 inhibitors 0 reviews Not rated
    Be the first
    fulvestrant systemic (Pro, More...)
    class: estrogen receptor antagonists, hormones/antineoplastics 0 reviews Not rated
    Be the first
    esterified estrogens systemic (More...)
    class: estrogens 0 reviews Not rated
    Be the first
    eribulin systemic (Pro, More...)
    class: mitotic inhibitors 0 reviews Not rated
    Be the first
    cyclophosphamide systemic (Pro, More...)
    class: alkylating agents 0 reviews Not rated
    Be the first
    fluorouracil systemic (Pro, More...)
    class: antimetabolites 0 reviews Not rated
    Be the first
    fluoxymesterone systemic (Pro, More...)
    class: androgens and anabolic steroids, hormones/antineoplastics 0 reviews Not rated
    Be the first
    ixabepilone systemic (Pro, More...)
    class: mitotic inhibitors 0 reviews Not rated
    Be the first
    aminoglutethimide systemic (More...)
    class: adrenal corticosteroid inhibitors 0 reviews Not rated
    Be the first
    methotrexate systemic (Pro, More...)
    class: antimetabolites, antipsoriatics, antirheumatics, other immunosuppressants

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
GALE
2.23+0.02(+0.90%)Sep 16 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.